PSMA-PET Guided Radiation Therapy

Official Title

PSMA-PET Guided Radiation Therapy in Patients With High-Risk, Recurrent, or Oligometastatic Prostate Cancer


PSMA PET/CT has demonstrated higher sensitivity in detecting metastases than current imaging standard of care (CT and bone scan). [18F]DCFPyL is a promising high-sensitivity second generation PSMA-targeted urea-based PET probe. The hypothesis is that definitive radiation therapy (RT) informed by PSMA-PET findings will lead to improved cancer control outcomes compared to RT guided by conventional staging only. This study utilizes cmRCT design in companion to PERA (Partnership initiative for the Evaluation of technological innovation in Radiation Therapy).

Trial Description

Primary Outcome:

  • Failure-free survival
Secondary Outcome:
  • Acute and delayed toxicities
  • Rate of failure
  • Survival
  • Health-related quality of life
  • Detection yield of PSMA PET imaging

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society